Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Hepatocellular Carcinoma
Explore 499 assets in Hepatocellular Carcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Riboscience, LLC.
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07175441CT.gov Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07511504CT.gov Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07489976CT.gov IIT2025-03-YANG-LIFT-HCC | — | Recruiting | — | — | — |
NCT07166406CT.gov Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | — | Recruiting | — | — | — |
NCT07122089CT.gov Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis | — | Recruiting | — | — | — |
NCT07174570CT.gov Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer | — | Recruiting | — | — | — |
NCT06904170CT.gov Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06608940CT.gov BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT06880523CT.gov STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06994299CT.gov A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
Show 38 more trialsShow fewer
NCT07081633CT.gov Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT06999694CT.gov Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | — | Recruiting | — | — | — |
NCT06999707CT.gov Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | — | Recruiting | — | — | — |
NCT06921785CT.gov Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06911255CT.gov Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06710223CT.gov Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | — | Recruiting | — | — | — |
NCT06698250CT.gov Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | — | Recruiting | — | — | — |
NCT06526104CT.gov Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | — | Recruiting | — | — | — |
NCT06045975CT.gov Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure | — | Active Not Recruiting | — | — | — |
NCT06109272CT.gov A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT06117891CT.gov An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT05063565CT.gov TheraSphere With Durvalumab and Tremelimumab for HCC | — | Active Not Recruiting | — | — | — |
NCT05440864CT.gov Durvalumab and Tremelimumab in Resectable HCC | — | Recruiting | — | — | — |
NCT05451043CT.gov Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | — | Recruiting | — | — | — |
NCT05883644CT.gov Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | — | Active Not Recruiting | — | — | — |
NCT05864755CT.gov HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05701488CT.gov SIRT With Tremelimumab and Durvalumab for Resectable HCC | — | Recruiting | — | — | — |
NCT05844046CT.gov Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients | — | Recruiting | — | — | — |
NCT05557838CT.gov Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma | — | Recruiting | — | — | — |
NCT05809869CT.gov Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05301842CT.gov Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | — | Active Not Recruiting | — | — | — |
NCT04430452CT.gov Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05113290CT.gov Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | — | Unknown | — | — | — |
NCT05027425CT.gov Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | — | Terminated | — | — | — |
NCT04605731CT.gov Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT03937830CT.gov Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04522544CT.gov Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | — | Recruiting | — | — | — |
NCT04988945CT.gov TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT03638141CT.gov CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | — | Completed | — | — | — |
NCT03539822CT.gov Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | — | Recruiting | — | — | — |
NCT03482102CT.gov Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | — | Active Not Recruiting | — | — | — |
NCT03298451CT.gov Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT02821754CT.gov A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | — | Completed | — | — | — |
NCT02519348CT.gov A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT01853618CT.gov Tremelimumab With Chemoembolization or Ablation for Liver Cancer | — | Completed | — | — | — |
NCT01869088CT.gov TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT01008358CT.gov Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT05345678CT.gov Himalaya Early Access Program | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer (this asset) | Riboscience, LLC. | Approved | B · 63 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | BB · 68 |
| Biliary Tract Neoplasm | — | P2 | BB · 66 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-ctla-4-antigen-human-monoclonal-cp-675206-clone-1121-heavy-chain-disulphide-with-human-monoclonal-cp-675206-clone-1121-light-chain-dimer-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →